Posted by Michael Wonder on 20 Feb 2025
Doron Therapeutics receives FDA regenerative medicine advanced therapy designation for Motys for treatment of symptoms associated with osteoarthritis
19 February 2025 - Doron Therapeutics today announced that the US FDA has granted regenerative medicine advanced therapy designation to Motys, its lead placental tissue derived biologic in clinical development for the treatment of symptoms associated with knee osteoarthritis.
In addition to regenerative advanced therapy designation, Motys was also granted fast track designation by FDA.
